PARP16

Across TCGA pan-cancer cohorts, PARP16 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PARP16 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PARP16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARP16 expression acts as an unfavorable survival marker.

COAD, SKCM, and STAD are the cancer types where PARP16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.168	0.806	.002	12	view →
SKCM	OS	Median	All	0.179	0.781	<.001	10	view →
STAD	OS	Median	III,IV	0.003	0.630	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PARP16–COAD (OS)

Open the COAD breakdown →